BCMA CAR-T
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 1
- Enrollment
- 40 patients (estimated)
- Sponsors
- Arcellx, Inc., Kite, A Gilead Company
- Collaborators
- Arcellx, Inc.
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1043
- NCT Identifier
- NCT04155749
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.